Vanguard Group’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-3,422,721
| Closed | -$30.7M | – | 4159 |
|
|
2016
Q3 | $30.7M | Buy |
3,422,721
+25,096
| +0.7% | +$178K | ﹤0.01% | 2161 |
|
|
2016
Q2 | $18.2M | Sell |
3,397,625
-11,561
| -0.3% | -$59.3K | ﹤0.01% | 2366 |
|
|
2016
Q1 | $15.7M | Buy |
3,409,186
+394,390
| +13% | +$1.59M | ﹤0.01% | 2394 |
|
|
2015
Q4 | $15.7M | Buy |
3,014,796
+213,437
| +8% | +$1.24M | ﹤0.01% | 2412 |
|
|
2015
Q3 | $16.9M | Buy |
2,801,359
+81,543
| +3% | +$999K | ﹤0.01% | 2365 |
|
|
2015
Q2 | $42.9M | Buy |
2,719,816
+516,936
| +23% | +$6.28M | ﹤0.01% | 2022 |
|
|
2015
Q1 | $23.9M | Buy |
2,202,880
+130,417
| +6% | +$1.33M | ﹤0.01% | 2253 |
|
|
2014
Q4 | $21.8M | Buy |
2,072,463
+108,451
| +6% | +$1.06M | ﹤0.01% | 2204 |
|
|
2014
Q3 | $18.8M | Buy |
1,964,012
+57,513
| +3% | +$587K | ﹤0.01% | 2232 |
|
|
2014
Q2 | $22M | Buy |
1,906,499
+47,957
| +3% | +$437K | ﹤0.01% | 2185 |
|
|
2014
Q1 | $18.6M | Buy |
1,858,542
+146,047
| +9% | +$2.11M | ﹤0.01% | 2219 |
|
|
2013
Q4 | $22.3M | Buy |
1,712,495
+139,452
| +9% | +$1.92M | ﹤0.01% | 2129 |
|
|
2013
Q3 | $23.5M | Buy |
1,573,043
+310,729
| +25% | +$3.72M | ﹤0.01% | 2055 |
|
|
2013
Q2 | $11.8M | Buy |
+1,262,314
| New | +$8.55M | ﹤0.01% | 2261 |
|
Vanguard Group's RPTP Position: Q4 2016 in Review
Vanguard Group sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 3,422,721 shares — an estimated $30.7M sold.
Vanguard Group first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $42.9M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Vanguard Group reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Vanguard Group sold 3,422,721 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $30.7M.
- Vanguard Group first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Vanguard Group's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $42.9M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.